HOME > ACADEMIA
ACADEMIA
- Olumiant Expected to Shorten Time to Recovery from COVID-19: Infection Expert
May 12, 2021
- No. of New Lung Cancer Patients Fell 6.6% in 2020 amid COVID-19: Survey
May 11, 2021
- Survival Rate Declines for Some Cancers Even after 5 Years: NCC
April 28, 2021
- New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products
April 26, 2021
- Tokushukai Weighs Switches from Nichi-Iko Products after Biz Suspension Order
March 15, 2021
- COVID-19 Vaccination Should Be Avoided in Patients with Severe Hypersensitivity to PEG: Allergy Society
March 3, 2021
- Thorough Medication Guidance through Regional Collaboration Important for Rybelsus: Professor
February 22, 2021
- NCGM to Initiate Clinical Study of Convalescent Plasma Therapy for COVID-19 as Early as February
January 28, 2021
- Lynparza Got Prostate Cancer OK, but Reimbursement Issues Remain for CDx Costs: Professor
January 22, 2021
- Antitussive Cloperastine Strongly Attacks Cisplatin-Resistant Cancer Cells: Research Group
January 22, 2021
- Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids
January 7, 2021
- NCGM, Fujita Univ. to Join NIH’s Immunoglobulin Trial for COVID-19
December 24, 2020
- Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
December 24, 2020
- 4 Scientific Societies Call for COVID-19 Vaccine Recipient Registry
November 30, 2020
- Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL
November 25, 2020
- 5-Year Cancer Survival Rate at 68.6%, Largely Unchanged: NCC
November 24, 2020
- National Cancer Center Exploring Effectiveness of Frontline Use of Multigene Panel Testing for Solid Tumors
November 18, 2020
- University of the Ryukyus to Test Gout Drug Colchicine for COVID-19
November 6, 2020
- NCC Verifies Utility of Genomic Analysis by Liquid Biopsy
October 7, 2020
- Japanese Nephrology Society Publishes Recommendation on Use of HIF-PH Inhibitors
October 2, 2020
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…